DETAILED ACTION
This Office Action details a final action on the merits for the above referenced application No. Claims 1, 10, and 13-18 are pending in this application.
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Status of Claims
Claims 1, 15, and 18 are amended. Claims 2-9 and 10-12 are cancelled.
Response to Amendment
The claim amendments filed on 28 Sep. 2026 have been entered.
Response to Arguments
In view of Applicants amendments, the rejection of claims 15 and 18 under 35 USC 112(a) because the specification not reasonably provide enablement for preventing neo-angiogenesis and/or angiogenesis is withdrawn.
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.
Claim(s) 1, 10, 13-14 and 17-18 is/are rejected under 35 U.S.C. 102(a)(1),(2) as being anticipated by Wurzer et al. (WO 2019/020831 A1; published 31 Jan. 2019) for the reasons cited in the Office action filed on 26 Mar. 2026.
Regarding claims 1-4, and 6-10, Wurzer et al. teach the PSMA ligand 10 that comprises the isomer
PNG
media_image1.png
303
700
media_image1.png
Greyscale
(pgs. 39, 77). Wurzer et al. provides for 177Lu- natF-10 and 68Ga-natF-10 (pg. 58, Fig. 31,32 and 34) and their use in small animal imaging experiments in LNCaP (prostate cancer) tumor bearing SCID mice (pgs. 58, 82). These compounds comprise a compound of instant formula (1) wherein M3+ is a Lu3+ (177Lu3+) or a Ga3+ (68Ga3+). Regarding claims 13-14, and 16-17, the small animal experiments read on a methods of imaging, treating, and/or diagnosing (prostate) cancer comprising administering a compound of claim 1 to a patient in need thereof.
Applicants’ Arguments
Applicants assert that the compound of pages 39 and 77 is not chelated to 177Lu3+. Wurzer discloses about a hundred of cations that may be chelated by the chelating group and Wurzer does not suggest that 177Lu3+ is the cation chelated to the compound of pages 39 and 77. Wurzer does not specify the chiral configurations of the long of the 177Lu-natF-10 on pg. 58. There is no teaching that the ligand of the compound claimed in the pending claims with the specific chiral configuration.
Applicant's arguments filed 6 Oct. 2026 have been fully considered but they are not persuasive. Wurzer discloses the 177Lu-natF-10 as a stereoisomeric mixture that comprises the isomer compound of formula (I) complexing 177Lu3+ such that instant M3+ is 177Lu3+. At pgs. 38-39, compound 10 is identified as a racemic compound comprising the claimed isomer. Accordingly, the 177Lu-natF-10 disclosed in Wurzer and pharmaceutical composition thereof anticipates claims as amended because the 177Lu-natF-10 comprises the claimed stereoisomer of formula (1) wherein M3+ is 177Lu3+. At no place does Wurzer teach or suggest that the 177Lu-natF-10 comprising the 10 identified as racemic comprises an unidentified stereoisomer different from the stereoisomeric configuration of formula (1).
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Claim(s) 1, 10, and 13-18 is/are rejected under 35 U.S.C. 103 as being unpatentable over Wurzer et al. (WO 2019/020831 A1; published 31 Jan. 2019) for the reasons cited in the Office action filed on 26 Mar. 2026.
Wurzer et al. teach as discussed above. Wurzer et al. teach dual mode radiotracer and therapeutics (see title). The invention provides for a ligand-SIFA conjugate comprising within a single molecule three separate moieties: (i) one or more ligands, (ii) a SIFA moiety, and (iii) one or more chelating groups optionally containing a chelated nonradioactive or radioactive cation (see abstract). The fluorine atom on the SIFA can be 19F or 18F (pg. 6). The hydrophilic chelator can be DOTAGA or DOTA (pgs. 7 and 13). Preferred cations include 68Ga, 225Ac, and 177Lu (pgs. 14, 48, and 89). Wurzer et al. teach 177Lu-natF-ligand 10 and log D of -3.59±0.05 and IC50 of 2.8±0.7 nM and an internalization of 184.1±116 (pgs. 78-82). Wurzer et al. teach biodistribution studies of 177Lu- natF-10 and 68Ga-natF-10 (pg. 58, Fig. 31,32 and 34). Wurzer et al. teach diagnosis, imaging or prevention of neoangiogenesis/angiogenesis (pgs.46, and 96). Wurzer et al. teach methods of imaging diagnosing or treating cancer wherein the cancer is prostate (pg. 96).
Wurzer et al. do not disclose a compound of claim 1 wherein M3+ is 225Ac3+ or the compound
PNG
media_image2.png
300
712
media_image2.png
Greyscale
wherein the F is an 18F or exemplify a method of diagnosing, imaging, or prevention neoangiogenesis and/or angiogenesis comprising administering the claimed compound.
However, it would have been obvious to a person of ordinary skill in the art before the effective filing date to modify Wurzer et al. by substituting the chelated radioactive cation with 225Ac as taught by Wurzer et al. because the substituting would have been expected to provide an equivalent PSMA ligand-SIFA-DOTA complex advantageously capable of radiotherapy of prostate cancer. It would have been obvious to a person of ordinary skill in the art before the effective filing date to modify Wurzer et al. by substituting the F with 18F to arrive at
PNG
media_image2.png
300
712
media_image2.png
Greyscale
as taught by Wurzer et al. because that compound would have been expected to provide an equivalent PSMA ligand-SIFA-DOTA complex that advantageously enables PET imaging using cyclotron produced 18F. It would have been obvious to a person of ordinary skill in the art before the effective filing date to modify Wurzer et al. by diagnosing, imaging, or preventing neoangiogenesis and/or angiogenesis comprising administering the compound of claim 1 or 10 to an patient in need thereof as taught by Wurzer et al. because it would have been expected to advantageously enable in vivo diagnosing, imaging, and/or preventing.
Claim(s) 1, 10, and 13-18 is/are rejected under 35 U.S.C. 103 as being unpatentable over STN RN 22781115-11-6 (entered 19 Feb. 2019), in view of Wester et al. (WO 2019/115547 A1; published 20 Jun. 2019) for the reasons cited in the Office action filed on 26 Mar. 2026.
STN RN 2271115-11-6 disclose the compound
PNG
media_image3.png
344
832
media_image3.png
Greyscale
.
STN RN 2271115-11-6 do not teach the compound
PNG
media_image4.png
245
562
media_image4.png
Greyscale
or Lu (177Lu), Ga (68Ga), and Ac (225Ac) complexes thereof. STN RN 2271115-11-6 do not further teach the compound
PNG
media_image2.png
300
712
media_image2.png
Greyscale
wherein the F is an 18F or exemplify a method of diagnosing, imaging, treating and/or preventing prostate cancer or neoangiogenesis and/or angiogenesis comprising administering the claimed compound.
Wester et al. teach PSMA ligands for imaging and endoradiotherapy (see title). Wester et al. teach compounds of formula (I)
PNG
media_image5.png
220
493
media_image5.png
Greyscale
wherein the -X2-L1-X1- is preferably
PNG
media_image6.png
33
305
media_image6.png
Greyscale
wherein R9A and R11A may be C1 to C10 alkanediyl substituted with -CO2H, and R10A may be a linear C2 to C10 alkanediyl, r may be 1, and Rm-X3- may be
PNG
media_image7.png
129
222
media_image7.png
Greyscale
or
PNG
media_image8.png
143
283
media_image8.png
Greyscale
(pg. 21). Preferred chelated cations include 177Lu, 68Ga, and 225Ac (see pg. 22). Wester et al. teach 18F (pg. 3) Wester et al. teach the compound
PNG
media_image9.png
135
459
media_image9.png
Greyscale
(see pg. 81; psma-46). Wester et al. teach the EDS group wherein R6B is a substituent containing an electron lone pair at the atom attached to the Ph ring (see pgs. 7, 38, 93). An EDS group is an electron dense substituent (see pg. 13) that leads to unexpected advantages including high affinity and improved internalization (see pg. 8). Endotherapeutic approaches with [177Lu]PSMA I&T demonstrated efficacy, tolerability and high safety potential. Wester et al. teach diagnosing and/or treating cancer including prostate cancer and neoangiogenesis/angiogenesis (pg. 54). Wester et al. teach pharmaceutical composition comprising a pharmaceutically acceptable carrier (pgs. 33-34).
It would have been obvious to a person of ordinary skill in the art before the effective filing date to modify STN RN 2271115-11-6 by substituting the DOTAGA chelator with a DOTA chelator and then form metal complex optionally wherein the metal is Lu (177Lu), Ga (68Ga), or Ac (225Ac) and optionally form a pharmaceutical composition with one of those compounds as taught by Wester et al. because the DOTA chelator would have expected to provide an equivalent chelator advantageously not comprising a stereocenter and because the Lu (177Lu), Ga (68Ga), or Ac (225Ac) complexes would have been expected to advantageously enable imaging and/or therapy. It would have been obvious to a person of ordinary skill in the art before the effective filing date to further modify STN RN 2271115-11-6 by further substituting 19F with 18F to arrive at
PNG
media_image2.png
300
712
media_image2.png
Greyscale
as taught by Wester et al. because substituting would have been expected to provide an equivalent PSMA ligand-SIFA-DOTA complex advantageously capable of PET imaging using cyclotron produced 18F. It would have been obvious to a person of ordinary skill in the art before the effective filing date to further modify STN RN 2271115-11-6 by further administering one of the obvious PSMA ligand-SIFA-DOTA complexes to a subject for imaging, treating, or diagnosing prostate cancer or for diagnosing or imaging neoangiogenesis and/or angiogenesis as taught by Wester et al. because the administering would have been expected to advantageously enable in vivo diagnosing, imaging or treating.
Applicants’ Arguments
Applicants assert that there is no teaching in Wurzer that the specific ligand compound of the pending claims is chelated to 177Lu3+. One of ordinary skill would not be motivated to select the specific ligand compound with the particular chiral configurations from eight stereoisomers and 177Lu3+ from about a hundred cations to arrive at the compound of the pending claims. The Office gives no reason why the compound of STN RN 2271115-11-6 should be selected as the lead compound. STN RN 2271115-11-6 does not teach anything else for one or ordinary skill in the art to select the compound disclosed therein as a lead compound. There are no suggestions in Wester for the modifications to arrive at the compound as claimed. The cited EDS group appears to be irrelevant to any potential modification of the lead compound to arrive at the compound claimed in the present application.
Applicants’ arguments filed 28 Sep. 2026 have been fully considered but they are not persuasive. As discussed above, Wurzer discloses the 177Lu-natF-10 that comprises the compound of instant formula (1) wherein M3+ is 177Lu3+. Anticipation is the epitome of obviousness. See In re May, 574 F.2d 1082, 197 USPQ 601 (CCPA 1978). The 177Lu-natF-10 is taught and suggested as suitable for treatment of prostate cancer. At pg. 38-39, Wurzer identifies the unchelated stereoisomer of formula (I) as a suitable replacement for compound 10. Reading a list and selecting a known compound to meet known requirement is no more ingenuous than selecting the last piece to put into last opening in a jig-saw puzzle. It is not invention. See Sinclair & Carroll Co. v. Interchemical Corp., 325 U.S. 327, 65 USPQ 297 (1945). The claimed compound of instant formula (1) complexing 177Lu would have been obvious to a person of ordinary skill in the art before the effective filing date because it would have been expected to enable imaging and therapy of PSMA associated cancer.
STN RN 2271115-11-6 discloses an unchelated PSMA inhibitor compound having the same stereoisomeric configuration as instant formula (I) but differs from instant formula (I) as amended because it is unchelated and comprises the DOTAGA chelator rather than the DOTA chelator. The selection of known material based on its suitability for its intended use supports a prima facie obviousness determination. MPEP 2144.07. Wester teaches the DOTA and DOTAGA chelators as equivalent for PSMA inhibitor compounds since both chelators enable complexing the preferred cation 177Lu3+ suitable for imaging and therapy of prostate cancer. It would have been obvious to a person of ordinary skill in the art before the effective filing date to modify the PSMA inhibitor compound disclosed by STN RN 2271115-11-6 by substituting the unchelated DOTAGA with 177Lu-DOTA to arrive at a compound of instant formula (I) and a pharmaceutical composition thereof because it would have been expected to enable imaging and therapy of prostate cancer with high efficacy, tolerability and high safety potential.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 1, 10, and 13-18 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-16 of U.S. Patent No. 11,413,360 B2, in view of Wester et al. (WO 2019/115547 A1; published 20 Jun. 2019) for the reasons cited in the Office action filed on 26 Mar. 2026.
Claims 1-16 of U.S. Patent No. 11,413,360 B2 claim the compound
PNG
media_image10.png
225
538
media_image10.png
Greyscale
or an individual isomer thereof optionally containing a chelated nonradioactive or radioactive metal cation and wherein the fluorine atom is 18F and wherein the chelated cation is selected from 68Ga, 177Lu, and 225Ac.
Claims 1-16 of U.S. Patent No. 11,413,360 B2 do claim a compound having the spatial arrangement of formula (1) or a Lu (177Lu), Ga (68Ga), or a Ac (225Ac) complex thereof or the compound
PNG
media_image2.png
300
712
media_image2.png
Greyscale
wherein the F is an 18F or claim a method of diagnosing, imaging, treating and/or preventing prostate cancer or neoangiogenesis and/or angiogenesis comprising administering the claimed compound.
Wester et al. teach as discussed above.
It would have been obvious to a person of ordinary skill in the art before the effective filing date to modify the compound of claims 1-16 of U.S. Patent No. 11,413,360 B2 so that stereocenters on the linker portion of the compound have the (R) configuration and optionally form a (177Lu), a Ga (68Ga), or a Ac (225Ac) complex thereof as part of a pharmaceutical composition as taught by Wester et al. because the (R) configuration would have been expected to advantageously provide an chiral pure derivative and because the complexes would have been expected to enable imaging and/or therapy.
It would have been obvious to a person of ordinary skill in the art before the effective filing date to further modify claims 1-16 of U.S. Patent No. 11,413,360 B2 by further substituting 19F with 18F to arrive at
PNG
media_image2.png
300
712
media_image2.png
Greyscale
as taught by Wester et al. because substituting would have been expected to provide an equivalent PSMA ligand-SIFA-DOTA complex advantageously capable of PET imaging using cyclotron produced 18F. It would have been obvious to a person of ordinary skill in the art before the effective filing date to further modify claims 1-16 of U.S. Patent No. 11,413,360 B2 by further administering one of the obvious PSMA ligand-SIFA-DOTA complexes to a subject for imaging, treating, or diagnosing prostate cancer or for diagnosing or imaging neoangiogenesis and/or angiogenesis as taught by Wester et al. because the administering would have been expected to advantageously enable in vivo diagnosing, imaging or treating.
Claims 1, 10, and 13-18 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-16 of U.S. Patent No. 12,390,540 B2, in view of Wester et al. (WO 2019/115547 A1; published 20 Jun. 2019) for the reasons cited in the Office action filed on 26 Mar. 2026.
Claims 1-16 of U.S. Patent No. 12,390,540 B2 claim the compound
PNG
media_image11.png
397
963
media_image11.png
Greyscale
and a pharmaceutical or diagnostic composition and optionally wherein the chelator contains a chelated cation selected from 68Ga, 177Lu, and 225Ac and optionally wherein the SIFA fluorine atom is 18F.
Claims 1-16 of U.S. Patent No. 12,390,540 B2 do claim a compound having the spatial arrangement of formula (1) or a Lu (177Lu), Ga (68Ga), or a Ac (225Ac) complex thereof or the compound
PNG
media_image2.png
300
712
media_image2.png
Greyscale
wherein the F is an 18F or claim a method of diagnosing, imaging, treating and/or preventing prostate cancer or neoangiogenesis and/or angiogenesis comprising administering the claimed compound.
Wester et al. teach as discussed above.
It would have been obvious to a person of ordinary skill in the art before the effective filing date to modify the compound of claims 1-16 of U.S. Patent No. 12,390,540 B2 so that stereocenters on the linker portion of the compound have the (R) configuration and optionally form a (177Lu), a Ga (68Ga), or a Ac (225Ac) complex thereof as part of a pharmaceutical composition as taught by Wester et al. because the (R) configuration would have been expected to advantageously provide an chiral pure derivative and because the complexes would have been expected to enable imaging and/or therapy.
It would have been obvious to a person of ordinary skill in the art before the effective filing date to further modify claims 1-16 of U.S. Patent No. 12,390,540 B2 by further substituting 19F with 18F to arrive at
PNG
media_image2.png
300
712
media_image2.png
Greyscale
as taught by Wester et al. because substituting would have been expected to provide an equivalent PSMA ligand-SIFA-DOTA complex advantageously capable of PET imaging using cyclotron produced 18F. It would have been obvious to a person of ordinary skill in the art before the effective filing date to further modify claims 1-16 of U.S. Patent No. 12,390,540 B2 by further administering one of the obvious PSMA ligand-SIFA-DOTA complexes to a subject for imaging, treating, or diagnosing prostate cancer or for diagnosing or imaging neoangiogenesis and/or angiogenesis as taught by Wester et al. because the administering would have been expected to advantageously enable in vivo diagnosing, imaging or treating.
Claims 1, 10, and 13-18 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-7 of U.S. Patent No. 12,453,787 B2, in view of Wester et al. (WO 2019/115547 A1; published 20 Jun. 2019) for the reasons cited in the Office action filed on 26 Mar. 2026.
Claims `1-7 of U.S. Patent No. 12,453,787 B2 claim the compound
PNG
media_image12.png
498
467
media_image12.png
Greyscale
optionally containing a chelated radioactive cation optionally wherein cation is 68Ga, 177Lu, or 225Ac.
Claims 1-7 of U.S. Patent No. 12,453,787 B2 do claim a compound having the spatial arrangement of formula (1) or a Lu (177Lu), Ga (68Ga), or a Ac (225Ac) complex thereof or the compound
PNG
media_image2.png
300
712
media_image2.png
Greyscale
wherein the F is an 18F or claim a method of diagnosing, imaging, treating and/or preventing prostate cancer or neoangiogenesis and/or angiogenesis comprising administering the claimed compound.
Wester et al. teach as discussed above.
It would have been obvious to a person of ordinary skill in the art before the effective filing date to modify the compound of claims 1-7 of U.S. Patent No. 12,453,787 B2 so that stereocenters on the linker portion of the compound have the (R) configuration and optionally form a (177Lu), a Ga (68Ga), or a Ac (225Ac) complex thereof as part of a pharmaceutical composition as taught by Wester et al. because the (R) configuration would have been expected to advantageously provide an chiral pure derivative and because the complexes would have been expected to enable imaging and/or therapy.
It would have been obvious to a person of ordinary skill in the art before the effective filing date to further modify claims 1-7 of U.S. Patent No. 12,453,787 B2 by further substituting 19F with 18F to arrive at
PNG
media_image2.png
300
712
media_image2.png
Greyscale
as taught by Wester et al. because substituting would have been expected to provide an equivalent PSMA ligand-SIFA-DOTA complex advantageously capable of PET imaging using cyclotron produced 18F. It would have been obvious to a person of ordinary skill in the art before the effective filing date to further modify claims 1-7 of U.S. Patent No. 12,453,787 B2 by further administering one of the obvious PSMA ligand-SIFA-DOTA complexes to a subject for imaging, treating, or diagnosing prostate cancer or for diagnosing or imaging neoangiogenesis and/or angiogenesis as taught by Wester et al. because the administering would have been expected to advantageously enable in vivo diagnosing, imaging or treating.
Claims 1, 10, and 13-18 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-14 of U.S. Patent No. 12,357,711 B2, in view of Wester et al. (WO 2019/115547 A1; published 20 Jun. 2019) for the reasons cited in the Office action filed on 26 Mar. 2026.
Claims 1-14 of U.S. Patent No. 12,357,711 B2 claim the compound
PNG
media_image13.png
369
958
media_image13.png
Greyscale
and a pharmaceutical or diagnostic composition and optionally wherein the chelated cation is selected from Ga and Ac and optionally wherein F is 18F and claims methods of imaging and/or diagnosing or treating cancer including prostate cancer and a method of diagnosing, imaging, or preventing neoangiogenesis/angiogenesis.
Claims 1-14 of U.S. Patent No. 12,357,711 B2 do not claim a compound of instant formula (1) wherein DOTA replaces DOTAGA and Lu (177Lu), Ga (68Ga), or Ac (225Ac) complexes thereof or the compound
PNG
media_image2.png
300
712
media_image2.png
Greyscale
wherein F is 18F.
Wester et al. teach as discussed above.
It would have been obvious to a person of ordinary skill in the art before the effective filing date to modify claims 1-14 of U.S. Patent No. 12,357,711 B2 by substituting DOTAGA with DOTA and then form Lu (177Lu), Ga (68Ga), or Ac (225Ac) complexes thereof as taught by Wester et al. because the DOTA chelator would have expected to provide an equivalent chelator advantageously not comprising a stereocenter and because the Lu (177Lu), Ga (68Ga), or Ac (225Ac) complexes would have been expected to advantageously enable imaging and/or therapy. It would have been obvious to a person of ordinary skill in the art before the effective filing date to further modify claims 1-14 of U.S. Patent No. 12,357,711 B2 by further substituting 19F with 18F to arrive at
PNG
media_image2.png
300
712
media_image2.png
Greyscale
as taught by Wester et al. because substituting would have been expected to provide an equivalent PSMA ligand-SIFA-DOTA complex advantageously capable of PET imaging using cyclotron produced 18F.
Claims 1, 10, and 13-18 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-6 of U.S. Patent No. 12,377,176 B2, in view of Wester et al. (WO 2019/115547 A1; published 20 Jun. 2019 for the reasons cited in the Office action filed on 26 Mar. 2026.
Claims 1-6 of U.S. Patent No. 12,377,176 B2 claim a compound having the chemical structure
PNG
media_image14.png
320
940
media_image14.png
Greyscale
and a pharmaceutical and diagnostic composition and methods of imaging and/or treating and/or diagnosing cancer including prostate cancer and a method of reducing angiogenesis.
Claims 1-6 of U.S. Patent No. 12,377,176 B2 do not claim a compound of instant formula (1) wherein DOTA replaces DOTAGA and Lu (177Lu), Ga (68Ga), or Ac (225Ac) complexes thereof or the compound
PNG
media_image2.png
300
712
media_image2.png
Greyscale
wherein F is 18F or claim a method of diagnosing, imaging, treating and/or preventing prostate cancer or neoangiogenesis and/or angiogenesis comprising administering the claimed compound.
Wester et al. teach as discussed above.
It would have been obvious to a person of ordinary skill in the art before the effective filing date to modify claims 1-6 of U.S. Patent No. 12,377,176 B2 by substituting DOTAGA with DOTA and then form Lu (177Lu), Ga (68Ga), or Ac (225Ac) complexes thereof as taught by Wester et al. because the DOTA chelator would have expected to provide an equivalent chelator advantageously not comprising a stereocenter and because the Lu (177Lu), Ga (68Ga), or Ac (225Ac) complexes would have been expected to advantageously enable imaging and/or therapy. It would have been obvious to a person of ordinary skill in the art before the effective filing date to further modify claims 1-6 of U.S. Patent No. 12,377,176 B2 by further substituting 19F with 18F to arrive at
PNG
media_image2.png
300
712
media_image2.png
Greyscale
as taught by Wester et al. because substituting would have been expected to provide an equivalent PSMA ligand-SIFA-DOTA complex advantageously capable of PET imaging using cyclotron produced 18F. It would have been obvious to a person of ordinary skill in the art before the effective filing date to further modify claims 1-6 of U.S. Patent No. 12,377,176 B2 by further administering one of the obvious PSMA ligand-SIFA-DOTA complexes to a subject for imaging, treating, or diagnosing prostate cancer or for diagnosing or imaging neoangiogenesis and/or angiogenesis as taught by Wester et al. because the administering would have been expected to advantageously enable in vivo diagnosing, imaging or treating.
Applicants’ Arguments
The response filed on 28 Sep. 2026 does not address the above NSDP rejections; accordingly the rejections are being maintained for the reasons cited in the Office action filed on 26 Mar. 2026.
Conclusion
THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SEAN R DONOHUE whose telephone number is (571)270-7441. The examiner can normally be reached on Monday - Friday, 8:00 - 5:00 EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Hartley can be reached on (571)272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/SEAN R. DONOHUE/
Examiner, Art Unit 1618
/Michael G. Hartley/Supervisory Patent Examiner, Art Unit 1618